Overview: Inhibin Immunohistochemistry TestIntroduction: The Inhibin Immunohistochemistry Test detects inhibin protein to diagnose ovarian or testicular tumors, causing swelling or pain. Following 2023 NCCN guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected gonadal tumors.
Other Names: Inhibin IHC Assay, Ovarian/Testicular Tumor IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Inhibin testing began in the 1990s with gonadal tumor research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects inhibin to diagnose ovarian or testicular tumors, guides treatment, and evaluates patients with swelling or pain.
Test Parameters: 1. Inhibin Protein
Pretest Condition: No fasting required. Collect tissue via biopsy or surgical resection. Report history of swelling, pain, or hormonal changes.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document swelling, pain, hormonal changes, or family history of ovarian/testicular tumors. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy or surgery.
Procedural Considerations: Uses immunohistochemistry to detect inhibin in gonadal tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for ovarian or testicular tumor diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive inhibin staining suggests granulosa cell tumors or Sertoli-Leydig cell tumors, guiding surgery or chemotherapy. Negative staining may require further marker testing.
Specialist Consultation: Consult an oncologist or gynecologist/urologist for result interpretation and treatment planning.
Additional Supporting Tests: AMH IHC, AFP, or pelvic ultrasound to confirm ovarian/testicular tumor diagnosis.
Test Limitations: Not specific to one tumor type; other conditions may express inhibin. Clinical correlation is needed.
References: NCCN Ovarian Cancer Guidelines, 2023; American Journal of Surgical Pathology, McCluggage WG, 2022.
